The fundamental principle which was the raison d'être for CerFlux and continues to ground our science and innovation at CerFlux is clear and enduring: improving cancer outcomes requires human-relevant, patient-centered insight across the entire molecule-to-medicine journey. From the outset, the ability to understand how individual tumors are likely to respond to therapy before treatment begins has served as a guiding North Star. Matching the right treatment to the right tumor at the bedside is not an endpoint for CerFlux, but a foundational expression of a broader scientific commitment to precision, relevance, and impact.

​

This commitment extends well beyond bedside clinical decision-making. Across discovery, lead optimization, preclinical development, translation, and delivery, oncology continues to rely on experimental models that fail to reflect human tumor biology with sufficient fidelity. These limitations perpetuate the persistent “valley of death,” where promising molecules falter and actionable insight arrives too late to influence upstream decisions. CerFlux was founded to confront this structural problem directly, with the belief that translational failure is not inevitable, but a consequence of the tools we choose to build and rely upon.

​

CerFlux pursues this vision relentlessly by developing biomimetic, human-relevant New Approach Methodologies (NAMs) that connect molecular discovery to human-relevant and patient-level decision-making in a continuous and predictive way. Through platforms designed to preserve and replicate native tumor architecture, physiological transport, and clinically meaningful context, CerFlux aims to replace fragmented handoffs with continuity and transform the traditional molecule-to-medicine pathway into a more efficient and informative expressway.

The publications, patents, and funded research presented on our Science and Innovation page reflect ongoing progress toward this goal. CerFlux invites collaborators who share this commitment to reshaping how cancer therapies are discovered, developed, and delivered so that - together - we can realize our vision to #CrushCancer.